Eli Lilly and Company
LLY
$1,017.97
-$34.02-3.23%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 65.18B | 59.42B | 53.26B | 49.00B | 45.04B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.18B | 59.42B | 53.26B | 49.00B | 45.04B |
| Cost of Revenue | 11.05B | 10.08B | 9.25B | 8.97B | 8.42B |
| Gross Profit | 54.13B | 49.34B | 44.01B | 40.03B | 36.63B |
| SG&A Expenses | 11.09B | 10.41B | 9.76B | 9.12B | 8.59B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.48B | 33.05B | 30.84B | 29.29B | 28.00B |
| Operating Income | 29.70B | 26.37B | 22.42B | 19.71B | 17.04B |
| Income Before Tax | 25.73B | 22.50B | 16.86B | 13.60B | 12.68B |
| Income Tax Expenses | 5.09B | 4.09B | 3.06B | 2.49B | 2.09B |
| Earnings from Continuing Operations | 20.64K | 18.41K | 13.80K | 11.11K | 10.59K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.64B | 18.41B | 13.80B | 11.11B | 10.59B |
| EBIT | 29.70B | 26.37B | 22.42B | 19.71B | 17.04B |
| EBITDA | 31.69B | 28.27B | 24.31B | 21.54B | 18.81B |
| EPS Basic | 22.99 | 20.48 | 15.33 | 12.32 | 11.74 |
| Normalized Basic EPS | 20.28 | 17.92 | 15.24 | 13.46 | 11.66 |
| EPS Diluted | 22.95 | 20.44 | 15.30 | 12.29 | 11.71 |
| Normalized Diluted EPS | 20.25 | 17.89 | 15.21 | 13.43 | 11.63 |
| Average Basic Shares Outstanding | 3.59B | 3.60B | 3.60B | 3.60B | 3.61B |
| Average Diluted Shares Outstanding | 3.60B | 3.60B | 3.61B | 3.61B | 3.62B |
| Dividend Per Share | 6.00 | 5.80 | 5.60 | 5.40 | 5.20 |
| Payout Ratio | 26.09% | 28.28% | 36.46% | 43.73% | 44.19% |